The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496
- Author
- EVENS, Andrew M1 ; FANGXIN HONG2 ; STIFF, Patrick J10 ; ADVANI, Ranjana11 ; MILLER, Thomas P12 ; HOPPE, Richard T11 ; KAHL, Brad S13 ; HORNING, SandraJ14 ; GORDON, Leo I3 ; FISHER, Richard I4 ; BARTLETT, Nancy L5 ; CONNORS, Joseph M6 ; GASCOYNE, Randy D6 ; WAGNER, Henry7 ; GOSPODAROWICZ, Mary8 ; CHESON, Bruce D9
[1] The University of Massacharsetts Medical School, Worcester, MA, United States
[2] Dana-Farber Cancer Institute and Harvard School of Public Health, Boston, MA, United States
[3] Northwestern University Feinberg School of Medicine, Chicago, IL, United States
[4] University of Rochester, Rochester, NY, United States
[5] Washington University, St. Louis, MO, United States
[6] BC Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada
[7] Penn State Cancer Institute, Hershey, PA, United States
[8] Princess Margaret Hospital, Toronto, ON, Canada
[9] Georgetown University Hospital, Washington, DC, United States
[10] Loyola University, Chicago, IL, United States
[11] University of Arizona, Tucson, AZ, United States
[12] Stanford University, Palo Alto, CA, United States
[13] University of Wisconsin, Madison, WI, United States
[14] Genentech, Inc., San Francisco, CA, United States - Source
British journal of haematology. 2013, Vol 161, Num 1, pp 76-86, 11 p ; ref : 3/4 p
- CODEN
- BJHEAL
- ISSN
- 0007-1048
- Scientific domain
- Medical oncology; Hematology
- Publisher
- Blackwell, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- Hodgkin lymphoma bleomycin lung toxicity elderly treatment-related toxicity
- Keyword (fr)
- Age Anticancéreux Bléomycine Cancérologie Dacarbazine Doxorubicine Efficacité traitement Essai clinique Hématologie Maladie de Hodgkin Personne âgée Poumon Toxicité Traitement Vinblastine Etats-Unis Agent alkylant Alcaloïde Anthracyclines Antimitotique Appareil respiratoire Cancer DNA topoisomerase (ATP-hydrolysing) Enzyme Glycopeptide Homme Hémopathie maligne Inhibiteur de la topoisomérase II Inhibiteur enzyme Isomerases Lymphome Peptide Syndrome lymphoprolifératif Amérique du Nord Amérique
- Keyword (en)
- Age Antineoplastic agent Bleomycin Cancerology Dacarbazine Doxorubicin Treatment efficiency Clinical trial Hematology Hodgkin disease Elderly Lung Toxicity Treatment Vinblastine United States Alkylating agent Alkaloid Anthracyclins Antimitotic Respiratory system Cancer DNA topoisomerase (ATP-hydrolysing) Enzyme Glycopeptide Human Malignant hemopathy Topoisomerase II inhibitor Enzyme inhibitor Isomerases Lymphoma Peptides Lymphoproliferative syndrome North America America
- Keyword (es)
- Edad Anticanceroso Bleomicina Cancerología Dacarbazina Doxorubicina Eficacia tratamiento Ensayo clínico Hematología Hodgkin enfermedad Anciano Pulmón Toxicidad Tratamiento Vinblastina Estados Unidos Agente alquilante Alcaloide Antraciclinas Antimitótico Aparato respiratorio Cáncer DNA topoisomerase (ATP-hydrolysing) Enzima Glicopéptido Hombre Hemopatía maligna Inhibidor topoisomerase II Inhibidor enzima Isomerases Linfoma Péptido Linfoproliferativo síndrome America del norte America
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Discipline
- Blood diseases Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27199431
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1111/bjh.12222 
https://dx.doi.org/10.1111/bjh.12222
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1111\/bjh.12222\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:203:\"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"161\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"76\";s:8:\"\u0000*\u0000epage\";s:2:\"86\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"EVENS\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Andrew M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:12:\"FANGXIN HONG\";i:1;s:16:\"STIFF, Patrick J\";i:2;s:15:\"ADVANI, Ranjana\";i:3;s:16:\"MILLER, Thomas P\";i:4;s:16:\"HOPPE, Richard T\";i:5;s:12:\"KAHL, Brad S\";i:6;s:16:\"HORNING, SandraJ\";i:7;s:13:\"GORDON, Leo I\";i:8;s:17:\"FISHER, Richard I\";i:9;s:17:\"BARTLETT, Nancy L\";i:10;s:17:\"CONNORS, Joseph M\";i:11;s:17:\"GASCOYNE, Randy D\";i:12;s:13:\"WAGNER, Henry\";i:13;s:19:\"GOSPODAROWICZ, Mary\";i:14;s:15:\"CHESON, Bruce D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:203:\"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1111\/bjh.12222\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:203:\"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"161\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"76\";s:8:\"\u0000*\u0000epage\";s:2:\"86\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"EVENS\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Andrew M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:12:\"FANGXIN HONG\";i:1;s:16:\"STIFF, Patrick J\";i:2;s:15:\"ADVANI, Ranjana\";i:3;s:16:\"MILLER, Thomas P\";i:4;s:16:\"HOPPE, Richard T\";i:5;s:12:\"KAHL, Brad S\";i:6;s:16:\"HORNING, SandraJ\";i:7;s:13:\"GORDON, Leo I\";i:8;s:17:\"FISHER, Richard I\";i:9;s:17:\"BARTLETT, Nancy L\";i:10;s:17:\"CONNORS, Joseph M\";i:11;s:17:\"GASCOYNE, Randy D\";i:12;s:13:\"WAGNER, Henry\";i:13;s:19:\"GOSPODAROWICZ, Mary\";i:14;s:15:\"CHESON, Bruce D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:203:\"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:17:\"10.1111\/bjh.12222\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1111\/bjh.12222\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:203:\"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"161\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"76\";s:8:\"\u0000*\u0000epage\";s:2:\"86\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"EVENS\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Andrew M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:12:\"FANGXIN HONG\";i:1;s:16:\"STIFF, Patrick J\";i:2;s:15:\"ADVANI, Ranjana\";i:3;s:16:\"MILLER, Thomas P\";i:4;s:16:\"HOPPE, Richard T\";i:5;s:12:\"KAHL, Brad S\";i:6;s:16:\"HORNING, SandraJ\";i:7;s:13:\"GORDON, Leo I\";i:8;s:17:\"FISHER, Richard I\";i:9;s:17:\"BARTLETT, Nancy L\";i:10;s:17:\"CONNORS, Joseph M\";i:11;s:17:\"GASCOYNE, Randy D\";i:12;s:13:\"WAGNER, Henry\";i:13;s:19:\"GOSPODAROWICZ, Mary\";i:14;s:15:\"CHESON, Bruce D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:203:\"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1111\/bjh.12222\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:203:\"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"161\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"76\";s:8:\"\u0000*\u0000epage\";s:2:\"86\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"EVENS\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Andrew M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:12:\"FANGXIN HONG\";i:1;s:16:\"STIFF, Patrick J\";i:2;s:15:\"ADVANI, Ranjana\";i:3;s:16:\"MILLER, Thomas P\";i:4;s:16:\"HOPPE, Richard T\";i:5;s:12:\"KAHL, Brad S\";i:6;s:16:\"HORNING, SandraJ\";i:7;s:13:\"GORDON, Leo I\";i:8;s:17:\"FISHER, Richard I\";i:9;s:17:\"BARTLETT, Nancy L\";i:10;s:17:\"CONNORS, Joseph M\";i:11;s:17:\"GASCOYNE, Randy D\";i:12;s:13:\"WAGNER, Henry\";i:13;s:19:\"GOSPODAROWICZ, Mary\";i:14;s:15:\"CHESON, Bruce D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:203:\"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1111\/bjh.12222\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:203:\"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"161\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"76\";s:8:\"\u0000*\u0000epage\";s:2:\"86\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"EVENS\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Andrew M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:12:\"FANGXIN HONG\";i:1;s:16:\"STIFF, Patrick J\";i:2;s:15:\"ADVANI, Ranjana\";i:3;s:16:\"MILLER, Thomas P\";i:4;s:16:\"HOPPE, Richard T\";i:5;s:12:\"KAHL, Brad S\";i:6;s:16:\"HORNING, SandraJ\";i:7;s:13:\"GORDON, Leo I\";i:8;s:17:\"FISHER, Richard I\";i:9;s:17:\"BARTLETT, Nancy L\";i:10;s:17:\"CONNORS, Joseph M\";i:11;s:17:\"GASCOYNE, Randy D\";i:12;s:13:\"WAGNER, Henry\";i:13;s:19:\"GOSPODAROWICZ, Mary\";i:14;s:15:\"CHESON, Bruce D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:203:\"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
